Last reviewed · How we verify
NCT04990596: CEPAGE
Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE)
trial testing additional blood sample in Drug Resistance in 37 participants. Completed in 28 January 2025.
27 March 2024
Quick facts
| Lead sponsor | Rennes University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 37 |
| Start date | 12 July 2021 |
| Primary completion | 27 March 2024 |
| Estimated completion | 28 January 2025 |
| Sites | 4 locations across France |
Drugs / interventions tested
- additional blood sample — full drug profile →
Conditions studied
- Drug Resistance — all drugs for Drug Resistance →
Sponsor
Rennes University Hospital
Who can join
Adults 50 to 100, any sex, with Drug Resistance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A clopidogrel resistance rate of 40-50% has been found in the population over 70 years of age, whereas biological resistance, associated with an increased risk of cardiovascular events, is observed in about 20-30% of younger patients. One hypothesis is that the active metabolite is less available in resistant patients. Indeed, 85% of the absorbed clopidogrel undergoes inactivation by esterases. Then the remaining fraction undergoes two steps of metabolisation to the active thiol metabolite by CYP450, essentially the isoform 2C19. In older adults, increased esterase activity and/or decreased CYP450 2C19 activity may lead to a decreased concentration of the active metabolite. Multiple chronic conditions and polypharmacy encountered in older individuals are associated with basal platelet hyperactivity, and may also contribute to a poor response to clopidogrel. No data on the relationship between platelet response and circulating metabolite levels, or on the determinants of response to clopidogrel, are currently available in the geriatric population. Therefore, we propose to analyse the relationship between age and platelet and extra-platelet mechanisms potentially involved in the variability of response to clopidogrel.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of age on <i>in vitro</i> metabolism of clopidogrel: a potential explanation for high on-treatment platelet reactivity in the elderly?
Pontis A, Delavenne X, Verdier MC, Hodin S, et al · · 2023 · PMID 36891520 · DOI 10.1016/j.rpth.2022.100014
Verify or expand the search:
- PubMed search for NCT04990596
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of additional blood sample
Trials testing the same drug.
- NCT03671928 — Study of Circulating Levels of Glicentin · NA · completed
- NCT03056404 — Research for Specific Proteins of Interest for the Serological Diagnosis of Bird Fancier's Lung · NA · completed
- NCT02858414 — Exploratory Study of Cellular Reservoirs in Blood From HIV Infected Patients · NA · completed
- NCT02854644 — Study of the Anti-tumoral Immune Response · NA · completed
- NCT02855775 — Monoclonal Antibodies Elimination in Breast Cancer Patient · NA · completed
Other recruiting trials for Drug Resistance
Currently open trials in the same condition.
- NCT07071103 — Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors · Phase 2 · recruiting
- NCT07073755 — Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, · recruiting
Other Rennes University Hospital trials
Trials by the same sponsor.
- NCT07527949 — PASTRAMI : Patient-specific Statistics for Microstructure-augmented Connectomics · NA · not yet recruiting
- NCT07449832 — Sperm Epigenome in Hodgkin Lymphoma · NA · not yet recruiting
- NCT06950398 — Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers · Phase 2 · not yet recruiting
- NCT07188753 — Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-dose Theta-b · NA · not yet recruiting
- NCT06898099 — Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care (HypERR) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04990596 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rennes University Hospital
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04990596.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing